Impact of Sonelokimab on Clinical and Imaging Outcomes in Axial Spondyloarthritis: Results of a Phase 2 Study - Report from EULAR 2026

Professor Xenofon Baraliakos, President of EULAR, presents pivotal data from a Phase 2 study evaluating the impact of sonelokimab, an IL-17A/F-inhibiting Nanobody, on clinical outcomes in axial spondyloarthritis. Highlighted at the EULAR 2026 Congress, this breakthrough recap explores how the integration of advanced 18F-NaF PET imaging and MRI provides unprecedented visualization of reduced bone inflammation and metabolic activity, opening new pathways for targeted biologic therapies.Video: https://medicaldigest.org/scientific-contents/interview:impact-sonelokimab-clinical-and-imaging-outcomes-axial-spondyloarthritis-results-phase-2-study